Lymphotoxin-beta receptor controls the development of chronic pain
Authors: Tumanov et al.
Journal: Cell Reports published: April 2026
Summary:
This article describes a new immune-system pathway that may help explain how acute pain becomes chronic pain. The researchers focused on the lymphotoxin-beta receptor, an immune-related receptor that appears to play an important role in sensory neurons and peripheral sensitization.
The key finding is that blocking this receptor may prevent the development of chronic pain before it becomes established. This is important because most current chronic pain treatments are aimed at temporary symptom relief after chronic pain already exists, rather than preventing the transition from acute to chronic pain.
The study is especially relevant to chemotherapy-induced neuropathic pain. Many cancer patients develop chronic neuropathic pain from chemotherapy, which can sometimes force physicians to reduce chemotherapy doses. That can interfere with optimal cancer treatment. The authors suggest that targeting the lymphotoxin-beta receptor pathway could potentially prevent this complication without broadly suppressing the immune system.
The researchers believe the lymphotoxin-beta receptor acts like an upstream “boss” molecule. After injury or chemotherapy, it may activate multiple downstream genes and inflammatory mediators that sensitize sensory neurons and drive chronic pain. By blocking this upstream signal, it may be possible to stop the entire cascade before chronic pain develops.
Clinical importance:
This research is promising because the drug pathway has already been explored in humans for autoimmune disease, although it was not successful for rheumatoid arthritis. That may shorten the path toward future clinical testing for pain prevention. However, the authors also note that dose and delivery will be critical, because systemic immune blockade could weaken the body’s ability to fight infection or cancer.
Bottom line:
This is an early but important study suggesting that chronic pain may be preventable in some settings by targeting the lymphotoxin-beta receptor pathway. The most immediate potential application may be chemotherapy-induced neuropathic pain, but the same mechanism may also apply to other types of chronic pain, including pain after burns or viral infections.
Thank you to Cell Reports for allowing us to summarize this article.